novo nordisk amycretin - Search News

Novo Nordisk, amycretin

Novo Nordisk next-gen shot shows 22% weight loss in early results

One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their weight in 36 weeks, according to early-stage trial results on Friday, boosting the drugmaker's shares.

Hosted on MSN · 1d

Novo Nordisk shares pop on early-stage weight loss drug trial results

The Danish pharmaceutical giant reported positive early-stage results for its once weekly amycretin obesity drug.

YAHOO!Finance · 1d

Novo Nordisk's Weekly Amycretin Delivers Up to 22% Weight Loss in Study, Stock Soars

Novo Nordisk A/S (NYSE:NVO) released topline results from a phase 1b/2a trial with amycretin intended for once-weekly subcutaneous administration. The trial investigated the safety, tolerability, pharmacokinetics,

1d

Novo Nordisk amycretin data helps rebut concerns, says BofA

After Novo Nordisk (NVO) reported that subcutaneous amycretin demonstrated up to 22% absolute weight loss at 36-weeks in a Phase 1/2a trial, ...

1don MSN

The Score: Novo Nordisk, Oracle, Netflix, and More Stocks That Defined the Week

Here are some of the major companies whose stocks moved on the week’s news.

ncbiotech.org3d

IMMvention Therapeutix to collaborate with Novo Nordisk on oral therapies for sickle cell, other chronic diseases

IMMvention Therapeutix, Inc., a Durham early-stage biotechnology company focused on discovering and developing human ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results